期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
骨来源恶性肿瘤临床疗效的评估 被引量:2
1
作者 谢璐 许婕 +4 位作者 李原 刘蓉 孙昆昆 沈丹华 郭卫 《中国肿瘤临床》 CAS CSCD 北大核心 2019年第4期184-189,共6页
目的:通过现有实体瘤临床评估体系,对骨来源恶性肿瘤术前化疗前后的影像学资料进行总结,对比病理学评估结果,进一步提出并完善适合骨来源恶性肿瘤疗效的临床评估体系。方法:回顾性分析自2014年6月至2017年3月就诊于北京大学人民医院的19... 目的:通过现有实体瘤临床评估体系,对骨来源恶性肿瘤术前化疗前后的影像学资料进行总结,对比病理学评估结果,进一步提出并完善适合骨来源恶性肿瘤疗效的临床评估体系。方法:回顾性分析自2014年6月至2017年3月就诊于北京大学人民医院的190例连续病例,最后纳入研究157例,通过病理学Huvos分级将病例进行分组,对术前化疗前后的临床资料(肿瘤最大径变化、代谢参数的变化,以及一些公认的描述性参数)进行差异性检验及通过受试者工作曲线(receiver operating characteristic curve,ROC)计算肿瘤各项参数的变化率对术前化疗病理反应的ROC曲线下面积,并判断病理学分级的截点。结果:对原发肢体骨包含软组织包块的病例,判断坏死率为100%、90%及50%的最大径变化率截点分别为86%、50.7%和0.02%,骨扫描的T/B值变化率对坏死率预测效果不好,而PET/CT的SUVmax变化率对应坏死率为90%和50%的截点分别为60.7%和31.4%;而骨性边界变清晰及骨性密度增高为90%以上的病理学特异性表现形式。对不含软组织包块的原发纯骨内病变的病例,尚未发现有意义的临床评估指标。对中轴骨(包括颌面骨、脊柱及骨盆等)的病灶,由于病例数少,临床评估的截点目前区分度不大。结论:本研究对骨来源肿瘤的疗效临床评估提出了更具体的定义和不同病理学分级的界值,该临床评估体系的完善需通过前瞻、多中心、大宗数据进一步验证和讨论。 展开更多
关键词 骨肉瘤 尤文肉瘤 临床评估 病理学评估 化疗 靶向治疗
下载PDF
BMPR2 and HIF1-α overexpression in resected osteosarcoma correlates with distant metastasis and patient survival 被引量:7
2
作者 Shidong Wang Tingting Ren +4 位作者 Yi Huang Xing Bao kunkun sun Danhua Shen Wei Guo 《Chinese Journal of Cancer Research》 SCIE CAS CSCD 2017年第5期447-454,共8页
Objective: Bone morphogenetic protein receptor 2(BMPR2) and hypoxia-inducible factor 1-α(HIF1-α) existed abnormal expression in several types of cancer. However, their expressions and related roles in osteosarc... Objective: Bone morphogenetic protein receptor 2(BMPR2) and hypoxia-inducible factor 1-α(HIF1-α) existed abnormal expression in several types of cancer. However, their expressions and related roles in osteosarcoma are largely unknown.Methods:To investigate the clinical significance of BMPR2 and HIF1-αin osteosarcoma,we analyzed their expression levels in 103 osteosarcoma specimens by immunochemistry.Meanwhile,we conducted a follow-up to examine the metastatic behavior and overall survival(OS)of osteosarcoma patients.Results:Among 103 tissues,61 cases had BMPR2-positive expression and 57 cases had HIF1-αpositive expression.A significant correlation was noticed between BMPR2 and HIF1-αexpression in osteosarcoma specimens(P=0.035).Receiver-operating characteristic(ROC)curves were calculated to investigate the predictive value of the two markers in tumor metastasis.By means of univariate and multivariate analysis,BMPR2 and HIF1-αexpression,as well as higher tumor grade,were identified as significant risk factors for OS in patients with osteosarcoma.Kaplan-Meier survival analysis revealed that the patients with BMPR2 and HIF1-αpositive expression had worse OS compared with patients with BMPR2-negative or HIF1-α-negative staining.Conclusions:It can be concluded that BMPR2 and HIF1-αexpression is highly correlated with metastatic behavior in patients with osteosarcoma and can serve as predictive markers for metastasis and OS of these patients. 展开更多
关键词 BMPR2 HIF1-α immunochemistry osteosarcoma survival
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部